Candel reports 3 of 6 rHGG patients alive >1 year after CAN-3110 multiple injections

Candel Therapeutics, Inc.

Phase 1b trial of CAN-3110 in recurrent high-grade glioma: 3/6 patients alive at 12.2, 13.0, and 18.7 months post-treatment.
Data show improved survival vs. historical controls; biopsies reveal near absence of tumor cells with dense lymphocyte infiltrates.
Radiologic pseudo-progression observed: post-treatment MRI enhancement despite tumor clearance on histology.
Presented at 2024 IOVC; also disclosed new IL-12/IL-15 multimodal immunotherapy candidate from enLIGHTEN platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.